Wexford Capital’s Nektar Therapeutics NKTR Stock Holding History

Wexford Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,000	Closed	-$1.13M	–	93
2015 Q2	$1.13M	Buy	+6,000	New	+$1.03M	0.3%	41

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wexford Capital's NKTR Position: Q3 2015 in Review

Wexford Capital sold out of Nektar Therapeutics (NKTR) in Q3 2015, closing a stake of 6,000 shares — an estimated $1.13M sold.

Wexford Capital first reported a position in NKTR in Q2 2015 and held it in 1 quarter. The position peaked at $1.13M in Q2 2015. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

Wexford Capital reported no remaining Nektar Therapeutics position as of Q3 2015 after selling out during the quarter.
Wexford Capital sold 6,000 Nektar Therapeutics shares in Q3 2015, an estimated $1.13M.
Wexford Capital first reported a position in Nektar Therapeutics in Q2 2015 and held it in 1 quarter.
Wexford Capital's Nektar Therapeutics position peaked at $1.13M in Q2 2015.
166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on Wexford Capital's 13F filing for Q3 2015, filed 13 Nov 2015.